源自腹膜后的恶性会厌瘤,临床病程凶险:病例报告。

IF 0.7 Q4 SURGERY
Ken Kunugitani, Satoshi Ogiso, Masakazu Fujimoto, Tomoaki Yoh, Hisaya Shirai, Shinya Okumura, Hirofumi Hirao, Takamichi Ishii, Akihiko Yoshida, Etsuro Hatano
{"title":"源自腹膜后的恶性会厌瘤,临床病程凶险:病例报告。","authors":"Ken Kunugitani, Satoshi Ogiso, Masakazu Fujimoto, Tomoaki Yoh, Hisaya Shirai, Shinya Okumura, Hirofumi Hirao, Takamichi Ishii, Akihiko Yoshida, Etsuro Hatano","doi":"10.1186/s40792-024-01915-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Malignant perineurioma is a rare malignant counterpart of perineurioma derived from perineural cells. Resection is the primary option for the treatment of malignant perineuriomas; however, patients often develop recurrence after resection, and effective treatment for advanced or recurrent lesions needs to be established. This report describes a 51-year-old female with a rare malignant perineurioma in the retroperitoneum, which contributing valuable insights to the literature.</p><p><strong>Case presentation: </strong>The patient presented with abdominal distension and the imaging work-up revealed a huge hemorrhagic tumor in the retroperitoneum and obstruction of inferior vena cava by the tumor. The patient underwent surgery retrieving the tumor combined with left hemiliver and retrohepatic vena cava, which confirmed the diagnosis of a malignant perineurioma based on histopathological and immunohistochemical examination. Cancer gene panel testing identified mutations in NF2. Radiotherapy was administered for peritoneal dissemination 2 months after surgery, and the patient died from disease progression 6 months after surgery.</p><p><strong>Conclusions: </strong>This rare case highlights the challenges in managing retroperitoneal malignant perineuriomas. The aggressive characteristics and limited treatment options for advanced malignant perineuriomas underscore the need for understanding the pathogenesis and developing effective systemic therapies. The identification of an NF2 mutation provides significant insights into potential therapeutic target.</p>","PeriodicalId":22096,"journal":{"name":"Surgical Case Reports","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091025/pdf/","citationCount":"0","resultStr":"{\"title\":\"Malignant perineurioma derived from the retroperitoneum with an aggressive clinical course: a case report.\",\"authors\":\"Ken Kunugitani, Satoshi Ogiso, Masakazu Fujimoto, Tomoaki Yoh, Hisaya Shirai, Shinya Okumura, Hirofumi Hirao, Takamichi Ishii, Akihiko Yoshida, Etsuro Hatano\",\"doi\":\"10.1186/s40792-024-01915-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Malignant perineurioma is a rare malignant counterpart of perineurioma derived from perineural cells. Resection is the primary option for the treatment of malignant perineuriomas; however, patients often develop recurrence after resection, and effective treatment for advanced or recurrent lesions needs to be established. This report describes a 51-year-old female with a rare malignant perineurioma in the retroperitoneum, which contributing valuable insights to the literature.</p><p><strong>Case presentation: </strong>The patient presented with abdominal distension and the imaging work-up revealed a huge hemorrhagic tumor in the retroperitoneum and obstruction of inferior vena cava by the tumor. The patient underwent surgery retrieving the tumor combined with left hemiliver and retrohepatic vena cava, which confirmed the diagnosis of a malignant perineurioma based on histopathological and immunohistochemical examination. Cancer gene panel testing identified mutations in NF2. Radiotherapy was administered for peritoneal dissemination 2 months after surgery, and the patient died from disease progression 6 months after surgery.</p><p><strong>Conclusions: </strong>This rare case highlights the challenges in managing retroperitoneal malignant perineuriomas. The aggressive characteristics and limited treatment options for advanced malignant perineuriomas underscore the need for understanding the pathogenesis and developing effective systemic therapies. The identification of an NF2 mutation provides significant insights into potential therapeutic target.</p>\",\"PeriodicalId\":22096,\"journal\":{\"name\":\"Surgical Case Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-05-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091025/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Surgical Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s40792-024-01915-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40792-024-01915-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

摘要

背景:恶性会厌瘤是会厌瘤的一种罕见恶性对应物,来源于会厌细胞。切除是治疗恶性会厌瘤的主要方法;然而,患者往往在切除后出现复发,因此需要建立针对晚期或复发病灶的有效治疗方法。本报告描述了一名51岁女性腹膜后恶性会厌瘤患者的情况,为相关文献提供了有价值的见解:患者因腹胀就诊,影像学检查发现腹膜后巨大出血性肿瘤,肿瘤阻塞了下腔静脉。根据组织病理学和免疫组化检查,确诊为恶性会厌瘤。癌症基因面板检测发现了 NF2 基因突变。术后2个月,患者因腹膜播散接受了放疗,术后6个月因病情恶化死亡:这一罕见病例凸显了治疗腹膜后恶性会厌瘤的挑战。晚期恶性会厌瘤的侵袭性特征和有限的治疗方案凸显了了解发病机制和开发有效系统疗法的必要性。NF2基因突变的确定为潜在的治疗靶点提供了重要启示。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Malignant perineurioma derived from the retroperitoneum with an aggressive clinical course: a case report.

Background: Malignant perineurioma is a rare malignant counterpart of perineurioma derived from perineural cells. Resection is the primary option for the treatment of malignant perineuriomas; however, patients often develop recurrence after resection, and effective treatment for advanced or recurrent lesions needs to be established. This report describes a 51-year-old female with a rare malignant perineurioma in the retroperitoneum, which contributing valuable insights to the literature.

Case presentation: The patient presented with abdominal distension and the imaging work-up revealed a huge hemorrhagic tumor in the retroperitoneum and obstruction of inferior vena cava by the tumor. The patient underwent surgery retrieving the tumor combined with left hemiliver and retrohepatic vena cava, which confirmed the diagnosis of a malignant perineurioma based on histopathological and immunohistochemical examination. Cancer gene panel testing identified mutations in NF2. Radiotherapy was administered for peritoneal dissemination 2 months after surgery, and the patient died from disease progression 6 months after surgery.

Conclusions: This rare case highlights the challenges in managing retroperitoneal malignant perineuriomas. The aggressive characteristics and limited treatment options for advanced malignant perineuriomas underscore the need for understanding the pathogenesis and developing effective systemic therapies. The identification of an NF2 mutation provides significant insights into potential therapeutic target.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
218
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信